3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Lymphoid
2
Conditions
Breast Neoplasms
4
Recurrence
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma, B-Cell
2
Burkitt Lymphoma
2
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Lymphoma, T-Cell
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large-Cell, Anaplastic
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Diseases
1
Anemia
1
Amyloidosis
1
Interventions
Rituximab
6
Lenalidomide
3
Bendamustine Hydrochloride
3
pirtobrutinib
2
Cyclophosphamide
2
venetoclax
1
umbralisib
1
ublituximab
1
tocilizumab
1
obinutuzumab
1
idelalisib
1
glofitamab
1
fludarabine
1
atezolizumab
1
acalabrutinib
1
Vincristine
1
Standard of Care
1
Prednisone
1
Doxorubicin
1
Brentuximab Vedotin
1
Appointments and Schedules
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Has announcements
×
Lymphoma, Non-Hodgkin
×
Cyclophosphamide
×
Clear all
NCT04245839
2025-11-05
TRANSCEND FL
Celgene
Phase 2
Active not recruiting
276 enrolled
2 FDA
NCT01777152
2021-11-30
ECHELON-2
Seagen Inc.
Phase 3
Completed
452 enrolled
16 charts
1 FDA